Daily Ards Research Analysis
Three studies advance ARDS science across prognosis, therapy, and supportive care. A multicenter cohort links the endothelial dysfunction index EASIX to higher short-term mortality in ARDS. A synthetic analog of an EPA-derived epoxide (OMT-28) improves survival and lung barrier integrity in murine lung injury, while a pediatric cohort suggests hemoadsorption may stabilize hemodynamics and oxygenation alongside extracorporeal support.
Summary
Three studies advance ARDS science across prognosis, therapy, and supportive care. A multicenter cohort links the endothelial dysfunction index EASIX to higher short-term mortality in ARDS. A synthetic analog of an EPA-derived epoxide (OMT-28) improves survival and lung barrier integrity in murine lung injury, while a pediatric cohort suggests hemoadsorption may stabilize hemodynamics and oxygenation alongside extracorporeal support.
Research Themes
- Endothelial dysfunction biomarkers for ARDS risk stratification (EASIX)
- Pro-resolving lipid analogs to protect alveolar-capillary barrier
- Extracorporeal hemoadsorption as adjunctive support in pediatrics
Selected Articles
1. Between endothelial activation and stress index (EASIX) and mortality in acute respiratory distress syndrome (ARDS) patients: a multicenter retrospective study.
Across two independent cohorts (MIMIC-IV and CQMU), higher Log2_EASIX at admission was associated with increased in-hospital and 28-, 60-, and 90-day mortality in ARDS. Associations persisted after adjustment and propensity score matching, supporting EASIX as an endothelial dysfunction-based prognostic biomarker.
Impact: EASIX uses routinely available labs to capture endothelial injury, a central ARDS mechanism, enabling rapid risk stratification. The multicenter, methodologically rigorous approach enhances generalizability.
Clinical Implications: Incorporating EASIX into ARDS admission assessments could enhance prognostic stratification and inform intensity of monitoring, enrollment criteria, or endothelial-targeted trial designs.
Key Findings
- Non-survivors had higher Log2_EASIX than survivors in MIMIC-IV (median 2.08 vs 1.35; P = 0.002).
- Non-survivors had higher Log2_EASIX in the CQMU cohort (median 2.34 vs 1.91; P < 0.0001).
- Elevated Log2_EASIX independently predicted higher in-hospital, 28-, 60-, and 90-day mortality after multivariable adjustment.
- Propensity score matching and Kaplan–Meier analyses confirmed worse survival in higher EASIX strata.
Methodological Strengths
- Two independent cohorts (MIMIC-IV and CQMU) with external validation.
- Robust analytics including Cox models, restricted cubic splines, propensity score matching, and Kaplan–Meier curves.
Limitations
- Retrospective design with potential residual confounding.
- Exact sample sizes and some baseline details are not reported in the abstract.
Future Directions: Prospective validation of EASIX thresholds in ARDS, integration into multimarker prognostic models, and trials to test endothelial-targeted interventions guided by EASIX risk strata.
BACKGROUND: The Endothelial Activation and Stress Index (EASIX), calculated as [lactate dehydrogenase (U/L) × creatinine (mg/dL)] ÷ platelet count (109/L), serves as a reliable biomarker for endothelial dysfunction. Endothelial damage significantly contributes to the pathophysiological mechanisms underlying acute respiratory distress syndrome (ARDS). However, the relationship between EASIX and ARDS patients remains to be fully elucidated. METHODS: To evaluate the relationship between EASIX and outcomes in patients with acute respiratory distress syndrome (ARDS), in two cohorts we used Cox proportional hazards models and applied restricted cubic spline methods. Then we stratify EASIX into higher Log2_EASIX and lower Log2_EASIX groups, matched baseline data from the two stratified groups in both cohorts using propensity score matching to reduce confounding bias. Additionally, we further analyzed the differences in clinical outcomes between the higher Log2_EASIX and lower Log2_EASIX groups and performed Kaplan-Meier analysis on the matched data. RESULTS: In the MIMIC-IV cohort, compared to the survival group, within the 28 days, the non-survival group had higher Log2_EASIX (Survival: Non-survival = 1.35 [0.16, 2.80]: 2.08 [0.79, 3.59], P = 0.002),and in the CQMU cohort, the non-survival group had higher Log2_EASIX (Survival: Non-survival = 1.91 [1.48, 2.43]: 2.34 [1.89, 3.01], P < 0.0001), Even after adjusting for potential confounders, individuals exhibiting elevated Log2_EASIX values still faced a greater risk of mortality during hospitalization and at 28-, 60-and 90-day post-admission. CONCLUSION: Elevated EASIX levels were found to be positively correlated with a higher risk of mortality in patients with ARDS. Assessing EASIX levels could be a promising biomarker for predicting overall survival in ARDS.
2. OMT-28, a synthetic analog of 17,18-epoxyeicosatetraenoic acid, mitigates lipopolysaccharide-induced lung injury in mice.
In an LPS-induced murine lung injury model, post-injury dosing of OMT-28 improved survival, reduced inflammatory mediators in BALF, limited vascular leak, and preserved tight junction protein ZO-1 while attenuating NF-κB activation. Findings support pro-resolving lipid analogs as candidate therapeutics to protect the alveolar-capillary barrier.
Impact: OMT-28 targets a biologically plausible resolution pathway and demonstrates survival benefit with post-injury administration, enhancing translational relevance for ARDS therapeutics.
Clinical Implications: While preclinical, results justify pharmacokinetic, dose-finding, and safety studies, followed by early-phase trials to test OMT-28 or related epoxide analogs in severe lung injury/ARDS.
Key Findings
- OMT-28 administered at 0.5 and 12 hours post-LPS significantly improved post-injury survival compared with vehicle.
- Reduced inflammatory cell infiltration and inhibited increased vascular permeability in the lung.
- Lower BALF levels of IL-1β, IL-6, CCL-2, and TNF-α with OMT-28 treatment.
- Prevented increased NF-κB phosphorylation and preserved tight junction protein ZO-1 expression.
Methodological Strengths
- Therapeutic (post-injury) dosing paradigm enhances translational relevance.
- Comprehensive readouts spanning survival, barrier integrity, cytokines, and signaling pathways.
Limitations
- Single-species LPS injury model; external validity to human ARDS uncertain.
- Sample size, dose–response, and pharmacokinetic data are not detailed in the abstract.
Future Directions: Test OMT-28 across diverse lung injury models, define pharmacology and dosing, and explore combination with lung-protective ventilation; advance to phase I/II trials if safety permits.
Acute respiratory distress syndrome (ARDS) is a severe condition characterized by intense lung inflammation. Excessive oxidative stress and sustained inflammation in humans with ARDS compromise the epithelial barrier's integrity, leading to pulmonary edema, hypoxemia, and rapidly progressive respiratory failure. A cytochrome P450 metabolite of eicosapentaenoic acid (EPA), i.e., 17,18-epoxyeicosatetraenoic acid (17,18-EEQ), exhibits potent anti-inflammatory properties. We investigated the therapeutic potential of OMT-28, a metabolically stable synthetic analog of 17,18-EEQ, in a murine model of lipopolysaccharide (LPS)-induced ARDS. OMT-28 or vehicle was administered at 0.5 and 12 h after an administration of LPS. The results demonstrated that compared to the vehicle, the OMT-28 treatment significantly improved the survival rate in the post-injury period. OMT-28 also alleviated LPS-induced inflammatory cell infiltration, inhibited increased vascular permeability, reduced the levels of IL-1β, IL-6, CCL-2, and TNF-α in bronchoalveolar lavage fluid (BALF), and prevented the rise in NF-κB phosphorylation and the decrease in tight junction protein Zonula occludens-1 (ZO-1) expression. The LPS-induced lung injury led to a reduced expression of the NAD
3. Hemoadsorption in critically ill neonatal and pediatric patients: a retrospective cohort study from a Latin American tertiary center.
In a single-center pediatric ICU cohort (n=11), hemoadsorption with CytoSorb used alongside CRRT and/or ECMO was associated with reduced PELOD-2 scores and suggested improvements in hemodynamics, oxygenation, and inflammatory status. These real-world data support further controlled studies in pediatric critical illness.
Impact: Provides rare pediatric data from a resource-limited setting on hemoadsorption integrated with extracorporeal support, informing feasibility and potential benefit.
Clinical Implications: Clinicians may consider hemoadsorption as an adjunct in select critically ill pediatric patients on CRRT/ECMO, while recognizing the need for controlled trials and careful monitoring.
Key Findings
- Eleven critically ill neonatal/pediatric patients received hemoadsorption with CytoSorb in a tertiary ICU.
- Hemoadsorption was associated with reductions in PELOD-2 scores (reported median decrease from 11 to 7 in abstract).
- Concomitant CRRT and/or ECMO were used, with suggested improvements in hemodynamic stability, oxygenation, and inflammation.
Methodological Strengths
- Real-world clinical cohort with integration of hemoadsorption and extracorporeal organ support.
- Focus on a pediatric population from a resource-limited setting, addressing a knowledge gap.
Limitations
- Small sample size (n=11) and retrospective single-center design without a control group.
- Incomplete quantitative reporting in the abstract and potential selection bias.
Future Directions: Prospective controlled pediatric studies to quantify effects on hemodynamics, oxygenation, inflammatory markers, and clinical outcomes, and to define patient selection criteria.
INTRODUCTION: Extracorporeal blood purification therapies, such as hemoadsorption, are increasingly utilized in intensive care to modulate inflammation, improve organ function, and reduce vasoactive support. However, data on their use in neonatal and pediatric populations remain limited, particularly in low-resource settings. This study aimed to evaluate clinical and laboratory outcomes in critically ill pediatric patients receiving hemoadsorption therapy alongside extracorporeal organ support. METHODS: We conducted a single-center retrospective cohort study in a tertiary neonatal and pediatric intensive care unit in Latin America. Eleven critically ill patients received hemoadsorption using CytoSorb RESULTS: Hemoadsorption was associated with reductions in PELOD-2 (median 11-7; DISCUSSION: Hemoadsorption in conjunction with CRRT and/or ECMO showed potential to improve hemodynamic stability, oxygenation, and inflammation in critically ill pediatric patients. These findings support further investigation of hemoadsorption as an adjunctive therapy in pediatric critical care, especially in resource-limited environments.